Neoadjuvant Immunotherapy in Melanoma: Where We Are and Where We Aren't.
- Published in:
- Oncology (08909091), 2023, v. 37, n. 10, p. 425
- By:
- Publication type:
- Article
Works matching IS 08909091 AND DT 2023 AND VI 37 AND IP 10
Results: 5
1
2
Secondary Pure Red Cell Aplasia During Daratumumab/Hyaluronidase Therapy for Multiple Myeloma.
- Published in:
- Oncology (08909091), 2023, v. 37, n. 10, p. 419, doi. 10.46883/25921006
- By:
- Publication type:
- Article
3
Price Gouging Among Shortages "Significantly Affects" Drug Supply.
- Published in:
- Oncology (08909091), 2023, v. 37, n. 10, p. 417
- By:
- Publication type:
- Article
4
Unusual Clinical Presentation of Clear Cell Sarcoma in a Young Woman.
- Published in:
- Oncology (08909091), 2023, v. 37, n. 10, p. 412, doi. 10.46883/25921005
- By:
- Publication type:
- Article
5
Multidisciplinary Team Approach Is Integral to Oncology Care.
- Published in:
- Oncology (08909091), 2023, v. 37, n. 10, p. 407
- By:
- Publication type:
- Article